- Home
- LB vs CRGX Comparison
LB vs CRGX Comparison
Compare LB & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LB
- CRGX
- Stock Information
- Founded
- LB 1992
- CRGX 2021
- Country
- LB United States
- CRGX United States
- Employees
- LB N/A
- CRGX N/A
- Industry
- LB
- CRGX
- Sector
- LB
- CRGX
- Exchange
- LB NYSE
- CRGX Nasdaq
- Market Cap
- LB 1.1B
- CRGX 964.5M
- IPO Year
- LB 2024
- CRGX 2023
- Fundamental
- Price
- LB $53.48
- CRGX $12.81
- Analyst Decision
- LB Buy
- CRGX Strong Buy
- Analyst Count
- LB 8
- CRGX 6
- Target Price
- LB $40.63
- CRGX $31.80
- AVG Volume (30 Days)
- LB 534.0K
- CRGX 224.8K
- Earning Date
- LB 11-06-2024
- CRGX 11-12-2024
- Dividend Yield
- LB 0.18%
- CRGX N/A
- EPS Growth
- LB N/A
- CRGX N/A
- EPS
- LB 0.30
- CRGX N/A
- Revenue
- LB $90,912,000.00
- CRGX N/A
- Revenue This Year
- LB $57.77
- CRGX N/A
- Revenue Next Year
- LB $44.23
- CRGX N/A
- P/E Ratio
- LB $179.97
- CRGX N/A
- Revenue Growth
- LB 26.93
- CRGX N/A
- 52 Week Low
- LB $18.75
- CRGX $13.10
- 52 Week High
- LB $80.82
- CRGX $33.92
- Technical
- Relative Strength Index (RSI)
- LB N/A
- CRGX 30.99
- Support Level
- LB N/A
- CRGX $13.33
- Resistance Level
- LB N/A
- CRGX $15.26
- Average True Range (ATR)
- LB 0.00
- CRGX 1.36
- MACD
- LB 0.00
- CRGX -0.30
- Stochastic Oscillator
- LB 0.00
- CRGX 3.51
About LB LANDBRIDGE COMPANY LLC
LandBridge Co LLC is engaged in managing land and resources to support and promote oil and natural gas development. It generate revenue streams from the use of its surface acreage, the sale of resources from land and oil and gas royalties.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.